Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Licensing revenue	$ 125,000	$ 125,000	$ 375,000	$ 375,000
Operating expenses:
Research and development	3,348,847	4,225,132	9,870,754	11,002,675
General and administrative	1,174,250	1,496,471	4,291,482	4,888,301
Total operating expenses	4,523,097	5,721,603	14,162,236	15,890,976
Loss from operations	(4,398,097)	(5,596,603)	(13,787,236)	(15,515,976)
Other income (expense):
Gain (loss) from change in valuation of earn-out milestone liability	1,246,151	(662,410)	670,172	(556,382)
Loss from impairment of in-process research and development	(2,520,000)		(2,520,000)
Investment income, net	524	8,133	3,941	21,832
Interest expense		(161,025)	(91,756)	(608,576)
Other income	93	2,218	3,545	1,965
Total other expense, net	(1,273,232)	(813,084)	(1,934,098)	(1,141,161)
Net loss	(5,671,329)	(6,409,687)	(15,721,334)	(16,657,137)
Deemed dividend related to warrant modification			(345,685)
Net loss attributable to common shareholders	$ (5,671,329)	$ (6,409,687)	$ (16,067,019)	$ (16,657,137)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.70)	$ (3.22)	$ (3.04)	$ (9.27)
Weighted average shares outstanding
Basic and diluted (in shares)	8,054,658	1,993,233	5,171,699	1,796,184